Skip to main content
Fig. 4 | BMC Medicine

Fig. 4

From: Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer

Fig. 4

Kaplan-Meier analysis of overall survival (OS) by genetic aberration and 3-lipid signature. OS by AR aberration and 3-lipid signature in the A discovery and B validation cohorts. OS by TP53 aberration and 3-lipid signature in the C discovery and D validation cohorts. OS by RB1 deletion and 3-lipid signature in the E discovery and F validation cohorts. OS by PI3K aberration and 3-lipid signature in the G discovery and H validation cohorts

Back to article page